Completed PHASE4 INTERVENTIONAL 2-arm NCT00162955

Prevention of CHOP-induced Chronic Cardiotoxicity

The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP

Sponsor: Osaka City University

Conditions Non-Hodgkin's Lymphoma

Interventions Valsartan

Updated 5 times since 2017 Last updated: May 7, 2012 Started: May 31, 2004 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Non-Hodgkin's Lymphoma, this trial is completed. The trial is conducted by Osaka City University and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Osaka City University

Data source: Osaka City University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Osaka, Japan